REGULATORY

Pay Heed to Company Burdens for Cost-Effective Evaluations, Kamoya Tells Chuikyo

May 28, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council (Chuikyo) should discuss the rollout of cost-effective assessments in Japan by taking due account of associated financial and personnel burdens placed on companies, a drug maker official said on May 27. “We’d like you…

To read the full story

FY2016 Drug Pricing Reform
August 18, 2015
HTAs Likely to Be Used for Re-Pricing of Listed Medicines
June 25, 2015
MHLW Eyes Budget Request to Set Up Cost-Effective Analysis Regime, Report Due Out Summer
May 28, 2015

REGULATORY

Daiichi, University of Tokyo Professor Win Japan’s PM Award for Ezharmia Development
January 20, 2026
Japan’s Lower House Poll Set for Feb. 8 after Takaichi Calls Snap Vote
January 20, 2026
Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead
January 19, 2026
Chuikyo OKs 3.5% Minimum NHI Price Hike, Sets Grace Period for New AG Pricing
January 19, 2026
Antivirals, Cancer Drugs Flagged in PMDA Risk Review
January 19, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Gist of FY2026 Drug Pricing Reform Outline

The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…

COMMENTARY

Wave of “World Firsts” Looms as 47 New Drug Candidates Line Up for 2026

By Shinya Sato

As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…

COLUMN

AI: Your New HR BFF (Not Your Replacement!)

By Philip Carrigan

Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…